Efficacy, Safety and Evolution of Cardiovascular Paramete... | NCT01114529

ID	Type	Description	Link
2009-015918-22	EudraCT Number

Label	Type	Description	Intervention Names
Everolimus	Experimental	Conversion from CNI to everolimus in combination with Myfortic and steroids	Drug: Everolimus
Calcineurin inhibitor, Prograf or Neoral	Active Comparator	Control arm: CNI continuation, either Prograf or Neoral in combination with Myfortic and steroids	Drug: Prograf or Neoral

Name	Type	Description	Arm Group Labels	Other Names
Everolimus	Drug	Early CNI to everolimus conversion	Everolimus	Certican, Zortress, RAD001

Measure	Description	Time Frame
Estimated Glomerular Filtration Rate (eGFR)	Assessment of renal function by comparing change from randomization to Month 12 in eGFR (MDRD4) between treatment arms (Full analysis set). Renal function was assessed by estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula. MDRD formula: GFR [mL/min/1.73m˄2] = 186.3(C˄-1.154)(A˄-0.203)GR. DEFINITIONS: C = serum concentration of creatinine [mg/dL]; A = age [years]; G = 0.742 when gender is female, otherwise G = 1; R = 1.21 when race is black, otherwise R = 1	Month 12

Measure	Description	Time Frame
Incidence of Composite Efficacy Endpoint for Each Arm at Month 12 and Month 24	Efficacy failure rate used the composite endpoint of: (1) treated biopsy-proven acute rejection (BPAR), (2) graft loss, or (3) death . A treated BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III and which was treated with anti-rejection therapy. **Graft loss is defined as when the allograft was presumed lost on the day the participant started dialysis and was not able to subsequently be removed from dialysis or re-transplanted.

Name	Affiliation	Role
Novartis Pharmaceuticals	Novartis Pharmaceuticals	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Novartis Investigative Site		CABA	Buenos Aires	C1118AAT	Argentina
Novartis Investigative Site

Label	URL
The American Journal of Transplantation, Poster Abstracts, 2016 Provider: John Wiley \& Sons, Ltd	View source

ID	Title	Description
FG000	Everolimus	Conversion from Calcineurin inhibitor (CNI) to everolimus in combination with Myfortic (mycophenolic acid) and steroids
FG001	Standard CNI (Tac)	Calcineurin inhibitor (CNI) continuation with Tacrolimus (Tac) in combination with Myfortic (mycophenolic acid), and steroids

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Agranulocytosis	Blood and lymphatic system disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Anaemia	Blood and lymphatic system disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Coagulopathy	Blood and lymphatic system disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Febrile neutropenia	Blood and lymphatic system disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Hypochromic anaemia	Blood and lymphatic system disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Leukopenia	Blood and lymphatic system disorders	17.1	Systematic Assessment	EG0004 affected346 at risk EG0013 affected238 at risk EG0023 affected121 at risk
Lymphadenopathy	Blood and lymphatic system disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Lymphocytic infiltration	Blood and lymphatic system disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0021 affected121 at risk
Neutropenia	Blood and lymphatic system disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0011 affected238 at risk EG0021 affected121 at risk
Normochromic normocytic anaemia	Blood and lymphatic system disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Thrombocytopenia	Blood and lymphatic system disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Thrombotic microangiopathy	Blood and lymphatic system disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Acute myocardial infarction	Cardiac disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Angina pectoris	Cardiac disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0021 affected121 at risk
Atrial fibrillation	Cardiac disorders	17.1	Systematic Assessment	EG0003 affected346 at risk EG0012 affected238 at risk EG0022 affected121 at risk
Atrial flutter	Cardiac disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Bradycardia	Cardiac disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Cardiac arrest	Cardiac disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0022 affected121 at risk
Cardiac failure	Cardiac disorders	17.1	Systematic Assessment	EG0004 affected346 at risk EG0012 affected238 at risk EG0021 affected121 at risk
Coronary artery disease	Cardiac disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Cyanosis	Cardiac disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Mitral valve incompetence	Cardiac disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Myocardial infarction	Cardiac disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0023 affected121 at risk
Myocardial ischaemia	Cardiac disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Palpitations	Cardiac disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Pericarditis	Cardiac disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0012 affected238 at risk EG0021 affected121 at risk
Supraventricular tachycardia	Cardiac disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Congenital cystic kidney disease	Congenital, familial and genetic disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Vertigo	Ear and labyrinth disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Hyperparathyroidism	Endocrine disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Abdominal hernia	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0012 affected238 at risk EG0020 affected121 at risk
Abdominal pain	Gastrointestinal disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0012 affected238 at risk EG0020 affected121 at risk
Abdominal pain upper	Gastrointestinal disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Anal fistula	Gastrointestinal disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Colitis	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0022 affected121 at risk
Constipation	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Crohn's disease	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Diarrhoea	Gastrointestinal disorders	17.1	Systematic Assessment	EG00015 affected346 at risk EG0019 affected238 at risk EG0024 affected121 at risk
Food poisoning	Gastrointestinal disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Gastric ulcer haemorrhage	Gastrointestinal disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Gastrointestinal haemorrhage	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Gastrointestinal obstruction	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Gastrointestinal toxicity	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Haematemesis	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Ileal fistula	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Ileus	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Intestinal ischaemia	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Large intestine perforation	Gastrointestinal disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Melaena	Gastrointestinal disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Mouth ulceration	Gastrointestinal disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Nausea	Gastrointestinal disorders	17.1	Systematic Assessment	EG0003 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Oedematous pancreatitis	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Pancreatitis	Gastrointestinal disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Pancreatitis acute	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0012 affected238 at risk EG0020 affected121 at risk
Rectal haemorrhage	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Small intestinal obstruction	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Stomatitis	Gastrointestinal disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Subileus	Gastrointestinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Umbilical hernia	Gastrointestinal disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Vomiting	Gastrointestinal disorders	17.1	Systematic Assessment	EG0003 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Death	General disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0021 affected121 at risk
Device leakage	General disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Gait disturbance	General disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
General physical health deterioration	General disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Generalised oedema	General disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Impaired healing	General disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Malaise	General disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Oedema	General disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Oedema peripheral	General disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0013 affected238 at risk EG0020 affected121 at risk
Pyrexia	General disorders	17.1	Systematic Assessment	EG00025 affected346 at risk EG0015 affected238 at risk EG0024 affected121 at risk
Sudden death	General disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Surgical failure	General disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Cholangitis	Hepatobiliary disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Cholecystitis chronic	Hepatobiliary disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0012 affected238 at risk EG0020 affected121 at risk
Cholelithiasis	Hepatobiliary disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Hepatitis	Hepatobiliary disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Hydrocholecystis	Hepatobiliary disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Liver disorder	Hepatobiliary disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Drug hypersensitivity	Immune system disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Kidney transplant rejection	Immune system disorders	17.1	Systematic Assessment	EG00019 affected346 at risk EG0015 affected238 at risk EG0028 affected121 at risk
Transplant rejection	Immune system disorders	17.1	Systematic Assessment	EG00023 affected346 at risk EG0015 affected238 at risk EG0029 affected121 at risk
Abdominal abscess	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Abscess limb	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Acute sinusitis	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Arthritis bacterial	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Asymptomatic bacteriuria	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
BK virus infection	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Bacterial infection	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Bacterial pyelonephritis	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Bacterial sepsis	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Bronchitis	Infections and infestations	17.1	Systematic Assessment	EG0003 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Bronchopneumonia	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0021 affected121 at risk
Catheter site abscess	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Cellulitis	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Clostridium difficile colitis	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Clostridium difficile infection	Infections and infestations	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Corona virus infection	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Cytomegalovirus colitis	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Cytomegalovirus infection	Infections and infestations	17.1	Systematic Assessment	EG0004 affected346 at risk EG0014 affected238 at risk EG0023 affected121 at risk
Cytomegalovirus viraemia	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0021 affected121 at risk
Dengue fever	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Device related infection	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Diarrhoea infectious	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Endocarditis	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Erysipelas	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Escherichia urinary tract infection	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Gastroenteritis	Infections and infestations	17.1	Systematic Assessment	EG00011 affected346 at risk EG0019 affected238 at risk EG0025 affected121 at risk
Gastroenteritis norovirus	Infections and infestations	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Gastroenteritis viral	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Gastrointestinal infection	Infections and infestations	17.1	Systematic Assessment	EG0003 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Gingivitis	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Graft infection	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
H1N1 influenza	Infections and infestations	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Herpes simplex	Infections and infestations	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Herpes zoster	Infections and infestations	17.1	Systematic Assessment	EG0003 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Infected lymphocele	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Infection	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Infectious pleural effusion	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Influenza	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Intervertebral discitis	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Kidney infection	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Liver abscess	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Lobar pneumonia	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Localised infection	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Lower respiratory tract infection	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Lung infection	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Mastitis	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Metapneumovirus infection	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Ophthalmic herpes zoster	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Osteomyelitis	Infections and infestations	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Peritoneal tuberculosis	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Peritonitis	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Peritonsillar abscess	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Pharyngitis	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0012 affected238 at risk EG0020 affected121 at risk
Pneumocystis jirovecii pneumonia	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Pneumonia	Infections and infestations	17.1	Systematic Assessment	EG00014 affected346 at risk EG0014 affected238 at risk EG0025 affected121 at risk
Pneumonia cytomegaloviral	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Pneumonia klebsiella	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Pneumonia mycoplasmal	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Polyomavirus-associated nephropathy	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Post procedural infection	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Postoperative wound infection	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Pulmonary sepsis	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Pulmonary tuberculosis	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Pyelonephritis	Infections and infestations	17.1	Systematic Assessment	EG00013 affected346 at risk EG0014 affected238 at risk EG0025 affected121 at risk
Pyelonephritis acute	Infections and infestations	17.1	Systematic Assessment	EG0004 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Pyelonephritis chronic	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Renal cyst infection	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Respiratory tract infection	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Rhinitis	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Rhinovirus infection	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Salmonellosis	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Scrub typhus	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Sepsis	Infections and infestations	17.1	Systematic Assessment	EG0006 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Septic necrosis	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Septic shock	Infections and infestations	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Shunt infection	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Systemic candida	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Tuberculosis	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Upper respiratory tract infection	Infections and infestations	17.1	Systematic Assessment	EG0002 affected346 at risk EG0012 affected238 at risk EG0020 affected121 at risk
Urinary tract infection	Infections and infestations	17.1	Systematic Assessment	EG00025 affected346 at risk EG00119 affected238 at risk EG0028 affected121 at risk
Urinary tract infection bacterial	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Urinary tract infection fungal	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Urosepsis	Infections and infestations	17.1	Systematic Assessment	EG0009 affected346 at risk EG0015 affected238 at risk EG0024 affected121 at risk
Vestibular neuronitis	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Viral infection	Infections and infestations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Wound infection	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Zygomycosis	Infections and infestations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Abdominal wound dehiscence	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Animal bite	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Arteriovenous fistula thrombosis	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Carbon monoxide poisoning	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Cervical vertebral fracture	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Colon injury	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Complications of transplanted kidney	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0005 affected346 at risk EG0015 affected238 at risk EG0020 affected121 at risk
Face injury	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Graft dysfunction	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0001 affected346 at risk EG0014 affected238 at risk EG0021 affected121 at risk
Graft loss	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0002 affected346 at risk EG0012 affected238 at risk EG0021 affected121 at risk
Humerus fracture	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Incisional hernia	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0003 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Limb traumatic amputation	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Post procedural haematuria	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Post procedural haemorrhage	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Postoperative wound complication	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Renal graft loss	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0021 affected121 at risk
Rib fracture	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Shunt aneurysm	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0000 affected346 at risk EG0012 affected238 at risk EG0020 affected121 at risk
Shunt thrombosis	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Spinal fracture	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Tibia fracture	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Toxicity to various agents	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0000 affected346 at risk EG0012 affected238 at risk EG0020 affected121 at risk
Transplant dysfunction	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Transplant failure	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0002 affected346 at risk EG0012 affected238 at risk EG0021 affected121 at risk
Traumatic arthritis	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Ureteric anastomosis complication	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Vascular pseudoaneurysm	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Wound	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Wound necrosis	Injury, poisoning and procedural complications	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Biopsy	Investigations	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Blood creatine increased	Investigations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Blood creatinine abnormal	Investigations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Blood creatinine increased	Investigations	17.1	Systematic Assessment	EG00017 affected346 at risk EG0016 affected238 at risk EG0025 affected121 at risk
C-reactive protein increased	Investigations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Creatinine renal clearance decreased	Investigations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Haemoglobin decreased	Investigations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Haemoglobin urine present	Investigations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Hepatic enzyme increased	Investigations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Liver function test abnormal	Investigations	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Protein urine present	Investigations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Weight decreased	Investigations	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Dehydration	Metabolism and nutrition disorders	17.1	Systematic Assessment	EG0003 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Diabetes mellitus	Metabolism and nutrition disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0015 affected238 at risk EG0021 affected121 at risk
Diabetes mellitus inadequate control	Metabolism and nutrition disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Diabetes with hyperosmolarity	Metabolism and nutrition disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Diabetic ketoacidosis	Metabolism and nutrition disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Fluid retention	Metabolism and nutrition disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Hypercalcaemia	Metabolism and nutrition disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Hyperglycaemia	Metabolism and nutrition disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Hyperosmolar state	Metabolism and nutrition disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Hypocalcaemia	Metabolism and nutrition disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Hypokalaemia	Metabolism and nutrition disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Hyponatraemia	Metabolism and nutrition disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Hypophosphataemia	Metabolism and nutrition disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Obesity	Metabolism and nutrition disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Type 1 diabetes mellitus	Metabolism and nutrition disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Arthralgia	Musculoskeletal and connective tissue disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Back pain	Musculoskeletal and connective tissue disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Intervertebral disc protrusion	Musculoskeletal and connective tissue disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0012 affected238 at risk EG0020 affected121 at risk
Lumbar spinal stenosis	Musculoskeletal and connective tissue disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Muscle haemorrhage	Musculoskeletal and connective tissue disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Myopathy	Musculoskeletal and connective tissue disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Osteoarthritis	Musculoskeletal and connective tissue disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0012 affected238 at risk EG0020 affected121 at risk
Osteonecrosis	Musculoskeletal and connective tissue disorders	17.1	Systematic Assessment	EG0003 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Pain in extremity	Musculoskeletal and connective tissue disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Spinal osteoarthritis	Musculoskeletal and connective tissue disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Adenocarcinoma gastric	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Basal cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0013 affected238 at risk EG0020 affected121 at risk
Bowen's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Brain neoplasm malignant	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Bronchial carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Colon cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Gastric cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Glioblastoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Hepatic cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0021 affected121 at risk
Hepatic cancer metastatic	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Invasive ductal breast carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Lentigo maligna	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Lung adenocarcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Lung neoplasm malignant	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0021 affected121 at risk
Metastases to spine	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Papillary thyroid cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Parathyroid tumour benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Prostate cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Rectal neoplasm	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Renal cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Renal cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Small cell lung cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Squamous cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0002 affected346 at risk EG0013 affected238 at risk EG0020 affected121 at risk
Squamous cell carcinoma of skin	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Cerebral infarction	Nervous system disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Cerebrovascular accident	Nervous system disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Dementia Alzheimer's type	Nervous system disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Dementia with Lewy bodies	Nervous system disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Dizziness	Nervous system disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Headache	Nervous system disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Ischaemic stroke	Nervous system disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Migraine	Nervous system disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Multifocal motor neuropathy	Nervous system disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Peripheral sensory neuropathy	Nervous system disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Confusional state	Psychiatric disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Delirium	Psychiatric disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Psychotic disorder	Psychiatric disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Acute prerenal failure	Renal and urinary disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Bladder obstruction	Renal and urinary disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Calculus urinary	Renal and urinary disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Cystitis haemorrhagic	Renal and urinary disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Dysuria	Renal and urinary disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Haematuria	Renal and urinary disorders	17.1	Systematic Assessment	EG0005 affected346 at risk EG0013 affected238 at risk EG0021 affected121 at risk
Hydronephrosis	Renal and urinary disorders	17.1	Systematic Assessment	EG0003 affected346 at risk EG0012 affected238 at risk EG0021 affected121 at risk
Kidney fibrosis	Renal and urinary disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Nephritis haemorrhagic	Renal and urinary disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Nephropathy toxic	Renal and urinary disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0021 affected121 at risk
Obstructive uropathy	Renal and urinary disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Oliguria	Renal and urinary disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Prerenal failure	Renal and urinary disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Proteinuria	Renal and urinary disorders	17.1	Systematic Assessment	EG0008 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Renal artery stenosis	Renal and urinary disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0012 affected238 at risk EG0020 affected121 at risk
Renal cyst	Renal and urinary disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Renal cyst haemorrhage	Renal and urinary disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Renal failure	Renal and urinary disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Renal failure acute	Renal and urinary disorders	17.1	Systematic Assessment	EG0007 affected346 at risk EG0013 affected238 at risk EG0027 affected121 at risk
Renal failure chronic	Renal and urinary disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Renal impairment	Renal and urinary disorders	17.1	Systematic Assessment	EG0006 affected346 at risk EG0016 affected238 at risk EG0022 affected121 at risk
Renal tubular atrophy	Renal and urinary disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Renal tubular necrosis	Renal and urinary disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Tubulointerstitial nephritis	Renal and urinary disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Ureteric obstruction	Renal and urinary disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Ureteric stenosis	Renal and urinary disorders	17.1	Systematic Assessment	EG0004 affected346 at risk EG0011 affected238 at risk EG0021 affected121 at risk
Urethral obstruction	Renal and urinary disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Urethral stenosis	Renal and urinary disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Urinary fistula	Renal and urinary disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Urinary tract obstruction	Renal and urinary disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Benign prostatic hyperplasia	Reproductive system and breast disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Epididymitis	Reproductive system and breast disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Ovarian cyst	Reproductive system and breast disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Pelvic haematoma	Reproductive system and breast disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Prostatitis	Reproductive system and breast disorders	17.1	Systematic Assessment	EG0004 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Dyspnoea	Respiratory, thoracic and mediastinal disorders	17.1	Systematic Assessment	EG0005 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Epistaxis	Respiratory, thoracic and mediastinal disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Lung disorder	Respiratory, thoracic and mediastinal disorders	17.1	Systematic Assessment	EG0003 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Obstructive airways disorder	Respiratory, thoracic and mediastinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Pleural effusion	Respiratory, thoracic and mediastinal disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Pneumonia aspiration	Respiratory, thoracic and mediastinal disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Pneumonitis	Respiratory, thoracic and mediastinal disorders	17.1	Systematic Assessment	EG0003 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Pneumothorax	Respiratory, thoracic and mediastinal disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Pulmonary alveolar haemorrhage	Respiratory, thoracic and mediastinal disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	17.1	Systematic Assessment	EG0003 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Pulmonary oedema	Respiratory, thoracic and mediastinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0022 affected121 at risk
Respiratory failure	Respiratory, thoracic and mediastinal disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Diabetic foot	Skin and subcutaneous tissue disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Skin ulcer	Skin and subcutaneous tissue disorders	17.1	Systematic Assessment	EG0003 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Arteriovenous fistula	Vascular disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0021 affected121 at risk
Deep vein thrombosis	Vascular disorders	17.1	Systematic Assessment	EG0006 affected346 at risk EG0012 affected238 at risk EG0020 affected121 at risk
Haematoma	Vascular disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0011 affected238 at risk EG0021 affected121 at risk
Haemodynamic instability	Vascular disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Hypertension	Vascular disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0022 affected121 at risk
Hypotension	Vascular disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Lymphocele	Vascular disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0022 affected121 at risk
Lymphoedema	Vascular disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Necrosis ischaemic	Vascular disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0011 affected238 at risk EG0020 affected121 at risk
Orthostatic hypotension	Vascular disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Peripheral artery stenosis	Vascular disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Peripheral artery thrombosis	Vascular disorders	17.1	Systematic Assessment	EG0000 affected346 at risk EG0012 affected238 at risk EG0020 affected121 at risk
Peripheral vascular disorder	Vascular disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Thrombophlebitis	Vascular disorders	17.1	Systematic Assessment	EG0002 affected346 at risk EG0010 affected238 at risk EG0021 affected121 at risk
Thrombosis	Vascular disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0012 affected238 at risk EG0020 affected121 at risk
Vena cava thrombosis	Vascular disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk
Venous thrombosis limb	Vascular disorders	17.1	Systematic Assessment	EG0001 affected346 at risk EG0010 affected238 at risk EG0020 affected121 at risk

ID	Title	Description
BG000	Everolimus	Conversion from Calcineurin inhibitor (CNI) to everolimus in combination with Myfortic (mycophenolic acid) and steroids
BG001	Standard CNI (Tac)	Calcineurin inhibitor (CNI) continuation with Tacrolimus (Tac) in combination with Myfortic (mycophenolic acid), and steroids
BG002	Standard CNI (CsA)	Calcineurin inhibitor (CNI) continuation with Cyclosporine (CsA) in combination with Myfortic (mycophenolic acid) and steroids
BG003	Total	Total of all reporting groups

ID	Term
D020123	Sirolimus
D018942	Macrolides
D007783	Lactones
D009930	Organic Chemicals
D003524	Cyclosporins
D010456	Peptides, Cyclic
D047028	Macrocyclic Compounds
D011083	Polycyclic Compounds
D010455	Peptides
D000602	Amino Acids, Peptides, and Proteins

ID	Title	Description	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Everolimus	Conversion from Calcineurin inhibitor (CNI) to everolimus in combination with Myfortic (mycophenolic acid) and steroids	188	346	316	346
EG001	Standard CNI (Tac)	Calcineurin inhibitor (CNI) continuation with Tacrolimus (Tac) in combination with Myfortic (mycophenolic acid) and steroids	118	238	216	238
EG002	Standard CNI (CsA)	Calcineurin inhibitor (CNI) continuation with Cyclosporine (CsA) in combination with Myfortic (mycophenolic acid) and steroids	58	121	103	121